MedPath

Internet-based Affect Focused Psychodynamic Therapy for Neuroticism: a Randomized Controlled Trial

Not Applicable
Not yet recruiting
Conditions
Trait Neuroticism
Registration Number
NCT06665321
Lead Sponsor
Linkoeping University
Brief Summary

The purpose of the study is to investigate if internet delivered affect-focused psychodynamic therapy (IPDT) leads to lowered levels of trait neuroticism compared to a wait-list control condition. The target group is adults (18+) who experience mild to moderate symptoms of anxiety and/or depression. The IPDT treatment consists of 8 modules that the participants will work with for 9 weeks, with therapist support. Participants will be recruited in Sweden with nationwide recruitment.

Detailed Description

This study is a randomized controlled trial with the aim to investigate if IPDT leads to lowered levels of trait neuroticism. Participants will either be randomized to the treatment which is based on Affect Phobia Therapy or to a wait-list control. Participants will have weekly contact with a therapist who will provide feedback and support.

Primary outcome measure is trait neuroticism (measured on the 24-Item Neuroticism scale of the IPIP-NEO-120). Secondary outcome measures will include measures of anxiety, depression, quality of life, emotion regulation, and defense mechanism adaptiveness. Emotion regulation and short measure of anxiety and depressive symptoms will be collected weekly throughout the treatment period. Pre-treatment measurement, post-treatment measurement, weekly measure, and one-year follow up is planned to be collected through an online survey.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
108
Inclusion Criteria
  • Score 5 points or more on either the PHQ-9 or GAD-7
  • 18 years or older
  • Ability to speak, read and write in Swedish
  • Have access to the internet and a smartphone, computer or other device
Exclusion Criteria
  • Severe psychiatric or somatic illness that makes participation difficult or impossible
  • Ongoing addiction
  • Acute suicidality
  • Other ongoing psychological treatment
  • Recent (within the latest month) changes in the dose of psychotropic medication or planned change of dose during the treatment weeks

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Neuroticism scale of the Maples et al (2014) IPIP NEO PI 120 Item representationChange between baseline, end of treatment after nine weeks and follow-up at 12 months after treatment termination.

Measure of trait neuroticism. Consists of 24 items. Each item is scored from 0-4 with a total range of 0-96. A higher score reflects a higher level of trait neuroticism.

Secondary Outcome Measures
NameTimeMethod
Eysenck Personality Questionnaire Revised - Shortform (EPQR-S)Change between baseline, end of treatment after nine weeks and follow-up at 12 months after treatment termination.

12-item measure of trait neuroticism. Each item is score yes or no. Range 0-12 with a higher score indicating higher levels of neuroticism.

Patient Health Questionnaire-9Change between baseline, end of treatment after nine weeks and follow-up at 12 months after treatment termination.

Measure depressive symptoms. Consist of nine items, scored from 0-3. A higher score indicates more depressive symptoms.

Generalized Anxiety Disorder-7Change between baseline, end of treatment after nine weeks and follow-up at 12 months after treatment termination.

Measures symptoms of anxiety. 7 items scored from 0-3, with a higher score indicating more anxiety symptoms.

Brunnsviken Brief Quality of life scaleChange between baseline, end of treatment after nine weeks and follow-up at 12 months after treatment termination.

Measures quality of life. 12 items scored from 0-4. A higher score indicates higher quality of life.

Difficulties in Emotion Regulation Scale-16Change between baseline, end of treatment after nine weeks and follow-up at 12 months after treatment termination. Will be measured on a weekly basis during the 9 weeks of the intervention period.

Measure of emotion regulation. Consists of 16 items scored from 1-5. A higher score indicates less adaptive emotion regulation.

Defense Mechanism Rating Scale - Self Report 30Change between baseline, end of treatment after nine weeks and follow-up at 12 months after treatment termination.

Measures adaptiveness of defense mechanisms. Consists of 30 items scored from 0-4. A higher overall defense score (ODF) indicates more more adaptive defense mechanisms.

Patient Health Questionnaire - 4Change between baseline, end of treatment after nine weeks. Will be measured on a weekly basis during the intervention.

Brief measurer of depressive and anxiety symptoms. Consists of 4 items, scored from 0-3. A higher score indicates more symptoms.

Trial Locations

Locations (1)

Department of Behavioral Sciences and Learning

🇸🇪

Linköping, Östergörland, Sweden

© Copyright 2025. All Rights Reserved by MedPath